Review article · 2026 · Open access

LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects

Björn Niebel, Wanyin Chen, Kaori Mukai, Christophe Henry

Drug Discovery Today, 31(2), 104601 · Published 12 January 2026 · DOI 10.1016/j.drudis.2026.104601

Open full textCite this paper

In brief

“LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects” is a 2026 review article by Björn Niebel and 3 co-authors, published in Drug Discovery Today. OpenAlex counts 10 citations as of 17 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Drug Discovery Today.

Citations
10
Most cited in
2026 (10)
Field-weighted impact
4.94
References
150
Authors
4

Abstract

Lysosome-targeting chimeras (LYTACs) have emerged as a powerful modality in the field of extracellular targeted protein degradation (eTPD). The proximity-inducing mode of action of LYTACs can be applied to a growing number of lysosome-targeting receptors (LTRs) and membrane-bound E3 ligases to degrade extracellular proteins. In this review, we highlight preceding eTPD approaches and discuss in depth the plethora of newly identified LTRs that can be exploited in a LYTAC molecule. To provide guidance in the fast-growing LYTAC field, we elaborate on parameters to assess the preclinical validation of the various TACnologies, highlight opportunities for engineering catalytic LYTACs, and finish with pharmacokinetic (PK) considerations.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Niebel, B., Chen, W., Mukai, K., & Henry, C. (2026). LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects. Drug Discovery Today, 31(2), 104601. https://doi.org/10.1016/j.drudis.2026.104601

MLA 9

Niebel, Björn, et al. “LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects.” Drug Discovery Today, vol. 31, no. 2, 2026, p. 104601. https://doi.org/10.1016/j.drudis.2026.104601.

Chicago

Niebel, Björn, Wanyin Chen, Kaori Mukai, and Christophe Henry. 2026. “LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects.” Drug Discovery Today 31 (2): 104601. https://doi.org/10.1016/j.drudis.2026.104601.

Harvard

Niebel, B. et al. (2026) ‘LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects’, Drug Discovery Today, 31(2), p. 104601. doi:10.1016/j.drudis.2026.104601.

IEEE

B. Niebel, W. Chen, K. Mukai, and C. Henry, “LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects,” Drug Discovery Today, vol. 31, no. 2, p. 104601, 2026, doi: 10.1016/j.drudis.2026.104601.

BibTeX

@article{niebel2026lytacs,
  title     = {{LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects}},
  author    = {Niebel, Björn and Chen, Wanyin and Mukai, Kaori and Henry, Christophe},
  journal   = {Drug Discovery Today},
  year      = {2026},
  volume    = {31},
  number    = {2},
  pages     = {104601},
  doi       = {10.1016/j.drudis.2026.104601},
  url       = {https://doi.org/10.1016/j.drudis.2026.104601}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • lysosome-targeting chimeras
  • preclinical validation
  • pharmacokinetics

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Niebel, B., Chen, W., Mukai, K., & Henry, C. (2026). LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects. Drug Discovery Today, 31(2), 104601. https://doi.org/10.1016/j.drudis.2026.104601

How many times has this paper been cited?

10 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Drug Discovery Today: sign in and open the full text from this page.

Who wrote this paper?

Björn Niebel, Wanyin Chen, Kaori Mukai, Christophe Henry.

What is the DOI of this paper?

10.1016/j.drudis.2026.104601, permanently at https://doi.org/10.1016/j.drudis.2026.104601. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.